Overview of the British Pharmacopoeia 2024
ZHAO Hui-fang
CHEN Wei-zhen
WANG Ya-wen
Abstract：The British Pharmacopoeia(BP)holds significant international influence in the pharmaceutical field and is closely concerned by experts and scholars in this field.The BP undergoes annual revisions,which not only keeps pace with the European Pharmacopoeia,but also incorporates additions,omissions,and improvements to some domestic drug standards.The publication of the new edition of BP further solidifies its authoritative position in the formulation of international drug standards,and provides a solid guarantee for the quality and safety of medicines worldwide.Based on the previous edition of BP,this article summarizes the revisions made in the 2024 edition on general monographs,specific monographs,appendices and other aspects,including additions of 38 monographs,omissions of 17 monographs,technical changes of 84 items and title changes of 8 monographs,etc.,as well as publishing several sets of non-mandatory guidance for the cell and gene therapy community and continuing to investigate and engage in the application of analytical quality by design(AQbD)concepts.It is hoped that this article will serve as a valuable reference for pharmacopoeia users and the revision of the Chinese Pharmacopoeia.
Keywords：British Pharmacopoeiageneral monographsspecific monographsappendicescomparison
Publication Date：2025-02-14
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 249-255 )